Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
Retrieved on:
Thursday, May 6, 2021
b'Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization\nPHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of S\xc3\xa9bastien Martel as Senior Vice President of Strategy and Business Development.
Key Points:
- b'Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization\nPHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of S\xc3\xa9bastien Martel as Senior Vice President of Strategy and Business Development.
- Mr. Martel will lead the Company\xe2\x80\x99s corporate strategy and business and corporate development endeavors.
- Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President, Global Head of Rare Diseases at Sanofi.
- In this role, Mr. Martel led the global rare disease business through multiple global product launches, commercialization, and disease awareness initiatives, in addition to guiding business development and portfolio strategy.